Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
MDAI 
Spectral AI Inc. (MDAI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/31/2025: MDAI (1-star) is a SELL. SELL since 3 days. Simulated Profits (-8.40%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $5.09
1 Year Target Price $5.09
| 2 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -49.67% | Avg. Invested days 26 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/31/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 65.37M USD | Price to earnings Ratio - | 1Y Target Price 5.09 |
Price to earnings Ratio - | 1Y Target Price 5.09 | ||
Volume (30-day avg) 3 | Beta 0.92 | 52 Weeks Range 1.01 - 3.25 | Updated Date 11/2/2025 |
52 Weeks Range 1.01 - 3.25 | Updated Date 11/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.7 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -51.97% | Operating Margin (TTM) -41.92% |
Management Effectiveness
Return on Assets (TTM) -20.97% | Return on Equity (TTM) -2308.32% |
Valuation
Trailing PE - | Forward PE 52.36 | Enterprise Value 61941821 | Price to Sales(TTM) 2.37 |
Enterprise Value 61941821 | Price to Sales(TTM) 2.37 | ||
Enterprise Value to Revenue 2.25 | Enterprise Value to EBITDA -3.41 | Shares Outstanding 30688895 | Shares Floating 18907630 |
Shares Outstanding 30688895 | Shares Floating 18907630 | ||
Percent Insiders 25.64 | Percent Institutions 12.59 |
Upturn AI SWOT
Spectral AI Inc.
Company Overview
History and Background
Spectral AI, Inc. (MDAX) was founded in 2008. It is a medical device company focused on the development and commercialization of its DeepView System for assessing burn wounds. It has evolved from research and development to commercializing a diagnostic tool to improve burn care.
Core Business Areas
- Burn Assessment: The core business revolves around providing diagnostic tools for burn wound assessment, primarily through their DeepView System. This involves hardware, software, and associated services.
- DeepView System: This system uses spectral imaging to provide clinicians with objective data on burn wound severity, aiming to improve treatment decisions and patient outcomes. This is sold direct to hospitals.
Leadership and Structure
Wensheng Fan is the Chief Executive Officer, and the company has a board of directors overseeing its operations. The organization structure is that of a med-tech company with focus on sales, marketing and R&D, with a traditional hierarchical structure.
Top Products and Market Share
Key Offerings
- DeepView System: The DeepView System is their primary product, utilizing proprietary spectral imaging to assess burn wound severity and predict healing outcomes. Market share data is not readily available. The competitors are companies that provide alternative burn assessment methods, including visual inspection, laser Doppler imaging, and biopsy. Specific competitors include companies making laser Doppler imagers and diagnostic consumables.
Market Dynamics
Industry Overview
The medical device industry for wound care is growing, driven by an aging population, rising incidence of chronic diseases, and increasing awareness of advanced wound care technologies. The burn care segment focuses on improving patient outcomes and reducing healthcare costs associated with burn injuries.
Positioning
Spectral AI positions itself as a leader in advanced burn wound assessment, differentiating its DeepView System through its ability to provide objective, non-invasive data for improved clinical decision-making. Their competitive advantage lies in the unique spectral imaging technology and the potential for improved patient outcomes.
Total Addressable Market (TAM)
The total addressable market for burn wound assessment is estimated to be in the hundreds of millions of dollars globally. Spectral AI's DeepView system has the potential to capture a significant portion of this market by providing a more accurate and objective assessment method than traditional approaches.
Upturn SWOT Analysis
Strengths
- Proprietary spectral imaging technology
- Potential for improved patient outcomes
- Objective, non-invasive assessment
- Early mover advantage in spectral burn assessment
Weaknesses
- Limited market penetration
- Dependence on a single product (DeepView)
- Requires significant capital for sales and marketing
- Requires regulatory approvals for international expansion
Opportunities
- Expansion into new geographic markets
- Development of new applications for spectral imaging
- Partnerships with healthcare providers and organizations
- Increasing awareness of advanced wound care technologies
Threats
- Competition from established medical device companies
- Technological advancements in alternative wound assessment methods
- Regulatory hurdles and reimbursement challenges
- Economic downturn impacting hospital budgets
Competitors and Market Share
Key Competitors
- Smith & Nephew (SNN)
- Integra LifeSciences (IART)
- Mu00f6lnlycke Health Care
Competitive Landscape
Spectral AIu2019s DeepView system offers a unique value proposition with spectral imaging for burn wound assessment. However, established competitors have broader product portfolios, larger sales forces, and greater market reach. Spectral AI needs to differentiate itself through clinical data and partnerships.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been slow, with revenue increasing year-over-year but with significant net losses.
Future Projections: Future growth depends on successful commercialization of DeepView, regulatory approvals, and market penetration. Analysts project revenue growth but continued losses in the near term.
Recent Initiatives: Recent initiatives include expanding the sales team, conducting clinical studies, and seeking regulatory approvals in new markets.
Summary
Spectral AI is a high-risk, high-reward company with a novel burn assessment technology. While DeepView presents a potentially significant advancement in burn care, the company faces substantial financial challenges and stiff competition. Success hinges on successful commercialization, regulatory approvals, and strategic partnerships. The company is dependent on continued capital infusion to fund operations.
Similar Stocks
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
- Publicly Available Market Data
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. The information is based on publicly available data, which may be subject to change. Investment decisions should be made after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Spectral AI Inc.
Exchange NASDAQ | Headquaters Dallas, TX, United States | ||
IPO Launch date 2021-04-06 | Co-Founder, Chief Innovation Strategist & Senior Advisor to the CEO Mr. Wensheng Fan | ||
Sector Healthcare | Industry Medical Devices | Full time employees 78 | Website https://www.spectral-ai.com |
Full time employees 78 | Website https://www.spectral-ai.com | ||
Spectral AI, Inc., an artificial intelligence (AI) company, focuses on predictive medical diagnostics in the United States. The company offers DeepView System, which uses proprietary AI algorithms to distinguish between fully damaged, partially damaged, and healthy human tissue characteristics invisible to the naked eye at the initial time point of wound presentation; and delivers a binary prediction on the wounds capacity to heal or not heal by a specified time point in the future to assist the physician in making a more accurate, timely, and informed decision regarding the treatment of the patient's wounds. Its system also includes MSI imaging technology, which consists of proprietary multi-spectral optics and sensors that capture injured tissue images; and AI-Burn software. Spectral AI, Inc. is headquartered in Dallas, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.